Viatris Greater China — Net Sales increased by 18.7% to $680.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.4%, from $555.50M to $680.10M. Over 4 years (FY 2021 to FY 2025), Greater China — Net Sales shows relatively stable performance with a 1.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market share or successful product adoption in China, while a decrease suggests competitive pressure or regulatory headwinds.
Represents the total revenue generated from the sale of pharmaceutical products and services within the Greater China ge...
Standard regional revenue reporting found in most multinational pharmaceutical companies.
vtrs_segment_greater_china_net_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $550.30M | $566.80M | $503.80M | $573.10M | $548.30M | $574.00M | $505.80M | $564.60M | $532.10M | $548.40M | $515.30M | $543.90M | $539.40M | $562.20M | $522.30M | $555.50M | $588.90M | $615.20M | $572.90M | $680.10M |
| QoQ Change | — | +3.0% | -11.1% | +13.8% | -4.3% | +4.7% | -11.9% | +11.6% | -5.8% | +3.1% | -6.0% | +5.6% | -0.8% | +4.2% | -7.1% | +6.4% | +6.0% | +4.5% | -6.9% | +18.7% |
| YoY Change | — | — | — | — | -0.4% | +1.3% | +0.4% | -1.5% | -3.0% | -4.5% | +1.9% | -3.7% | +1.4% | +2.5% | +1.4% | +2.1% | +9.2% | +9.4% | +9.7% | +22.4% |